DUBLIN , Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management will participate in a fireside chat on Wednesday, September 3, 2025 , at 6:30 a.m. PDT / 9:30 p.m. EDT / 2:30 p.m. IST . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals... Read More

DUBLIN , Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025 , at 4:30 p.m. EDT / 9:30 p.m. IST to provide an overview of clinical data, patient need and commercialization strategy for Modeyso™ (dordaviprone). Modeyso was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on August 6, 2025 , for the treatment of... Read More

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications For U.S. media and investors only DUBLIN and COPENHAGEN, Denmark , Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:... Read More

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an overall response rate in patients with progressive disease following prior therapy Company to host investor webcast on August 27, 2025 For U.S. media and investors only DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today... Read More

Renee Gala named as President and CEO, effective August 11 Total revenues of $1.05 billion in 2Q25 Xywav ® revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter Zepzelca ® granted Priority Review in 1L ES-SCLC DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2025 and updated financial guidance for... Read More

DUBLIN , July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter financial results and provide a business and financial update. Interested parties... Read More

Selection Follows Robust Succession Process Led by the Board Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors DUBLIN , July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala , Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025 ,... Read More

Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial DUBLIN , July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted conditional marketing authorization 1 for Ziihera ® (zanidatamab), a dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with... Read More

Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m. IST to review Zepzelca data For U.S. media and investors only... Read More

First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate analysis from the DUET trial cohort of patients taking >9 grams evaluated safety and changes in daytime sleepiness in adults with narcolepsy taking Xywav dosages of 9-12 grams per night For U.S. media and investors only DUBLIN , June... Read More

First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance Results presented at the ASCO... Read More

Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology For U.S. media and investors only DUBLIN , June 2, 2025 /PRNewswire/ - - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term... Read More

Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN , May 29, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be... Read More

DUBLIN , May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025 Fireside chat at 6:55 a.m. PDT / 9:55 a.m. EDT / 2:55 p.m. IST Goldman Sachs 46 th Annual Global Healthcare Conference on Wednesday, June 11, 2025 Fireside chat at 7:00 a.m. PDT / 10:00... Read More

Total revenues of $898 million in 1Q25 Xywav ® and Epidiolex ® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 Completed submission of sNDA for Zepzelca ® in 1L ES-SCLC Affirming 2025 revenue guidance; updating financial guidance to reflect Chimerix acquisition and impact of certain Xyrem ® antitrust litigation settlements DUBLIN , May 6, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today... Read More

DUBLIN , April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025 , at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals... Read More

DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the... Read More

Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca ® (lurbinectedin) and atezolizumab (Tecentriq ® ) combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients Long-term outcomes and survival data for Ziihera ® (zanidatamab-hrii) highlight its potential to... Read More

DUBLIN , April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update. Audio... Read More

Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN , April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned... Read More

DUBLIN , March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24 th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025 , at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals... Read More

Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia by Evaluating Low-Sodium Oxybate Treatment) study Novel analysis of real-world Epidiolex treatment patterns underscore importance of dose optimization for improved patient persistence For U.S. media and investors only DUBLIN ,... Read More

Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors Transaction to add near-term commercial opportunity to Jazz's pipeline Transaction represents total cash consideration of approximately $935 m illion, or $8.55 per share DUBLIN and DURHAM, N.C. , March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX)... Read More

Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 Xywav ® and Epidiolex ® revenues grew 16% and 15% year-over-year, respectively, in 2024 Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion Ziihera ® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 2025 guidance reflects continued top- and bottom-line growth DUBLIN , Feb. 25, 2025 /PRNewswire/ -- Jazz... Read More

DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45 th Annual Health Care Conference. Company management will participate in a fireside chat on Wednesday, March 5, 2025 , at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals... Read More

DUBLIN , Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 full year and fourth quarter financial results and provide a business and... Read More

DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43 rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025 , at 9:45 a.m. PST / 5:45 p.m. GMT . A live audio webcast of the presentation... Read More

Bruce Cozadd , Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN , Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc... Read More

Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex ® ) surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex... Read More

Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN , Dec. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera ® ) 50 mg/mL for injection for intravenous use is recommended by the National Comprehensive Cancer Network ® (NCCN... Read More

DUBLIN , Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024 , at 4:30 p.m. ET / 9:30 p.m. GMT to provide an overview of clinical data, patient need and commercialization strategy for Ziihera ® (zanidatamab-hrii), the first chemotherapy-free dual HER2-targeted bispecific antibody indicated for biliary tract cancer (BTC). Ziihera was... Read More

Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment DUBLIN , Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) from December 10-13 and 13... Read More

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical... Read More

DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024 , at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website... Read More

14% year-over-year revenue increase from combined key growth drivers Xywav ® , Epidiolex ® and Rylaze ® 2024 total revenue guidance affirmed at $4.0 to $4.1 billion Zanidatamab 2L BTC PDUFA date of November 29, 2024 Plan to submit sNDA for Zepzelca ® in 1L ES-SCLC in 1H25 DUBLIN , Nov. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updated... Read More

First presentation of top-line efficacy and safety results from the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial of adults with narcolepsy or idiopathic hypersomnia For U.S. media and investors only DUBLIN , Oct. 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts presenting data from across its sleep portfolio were... Read More

DUBLIN , Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 third quarter financial results and provide a business and financial update. Audio... Read More

Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN , Oct. 15, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca ® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq ® ) compared to... Read More

Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of 15.2 months and a Kaplan-Meier–estimated overall survival (OS) of 59% at 30 months DUBLIN , Sept. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median... Read More

New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA) DUBLIN , Sept. 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company, along with its partners, will present five abstracts at the... Read More

Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex ® ) Caregiver Survey on the real-world outcomes of Epidyolex ® (cannabidiol) treatment on patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) DUBLIN , Sept. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present eight abstracts at the... Read More

DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act... Read More

DUBLIN , Sept. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") to qualified institutional buyers... Read More

DUBLIN , Aug. 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution (marketed as Epidiolex ® /Epidyolex ® globally) as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC). The... Read More

DUBLIN , Aug. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 Fireside chat at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. IST Bank of America Global Healthcare Conference on Wednesday, September 18, 2024 Fireside chat at 7:55 a.m. PT / 10:55 a.m. ET /... Read More

15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® Oncology revenues grew 10% year-over-year Zanidatamab granted Priority Review by U.S. FDA for 2L BTC; PDUFA date of November 29, 2024 Near-term, late-stage pipeline catalysts anticipated through 2025 Narrowing 2024 total revenue guidance to $4.0 to $4.1 billion Affirming GAAP and non-GAAP adjusted net income guidance... Read More

Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations... Read More

DUBLIN , July 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that it has completed a repricing of the approximately $2.7 billion outstanding balance of its U.S. dollar term loans under its credit facility. The applicable margin above Term SOFR will be reduced by 75 basis points (from 300 basis points to 225 basis points) and the credit spread adjustment will be... Read More

DUBLIN , July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 second quarter financial results and provide a business and financial update. Audio... Read More

Ms. Pearce brings over 30 years of commercial experience and track record of success across global markets DUBLIN , July 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Samantha Pearce , Senior Vice President (SVP), Europe and International, has been promoted to Chief Commercial Officer (CCO) effective August 1, 2024 . Ms. Pearce joined Jazz as SVP, Europe and International, in 2020, and... Read More

DUBLIN , June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET). Suvecaltamide did not achieve statistical significance at 30mg... Read More

Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors With approximately two years of median follow-up, as of July 28, 2023 , median duration of response (DOR) increased by two months from initial analysis to 14.9 months DUBLIN , June 1, 2024 /PRNewswire/ -- Jazz... Read More

Thirteen abstracts, including five late-breaking abstracts, underscore Jazz's ongoing commitment to advancing the understanding and treatment of serious sleep disorders Oral presentation of XYLO study design to assess systolic blood pressure changes in oxybate patients after switching to low-sodium Xywav ® DUBLIN , May 30, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thirteen abstracts,... Read More

DUBLIN , May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6, 2024 Fireside chat at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST Goldman Sachs 45 th Annual Global Healthcare Conference on Wednesday, June 12, 2024 Fireside chat at 7:40 a.m. PT / 10:40 a.m.... Read More

Target Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract cancer DUBLIN , May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License... Read More

DUBLIN , May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States . This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life... Read More

DUBLIN , May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024 , in Las Vegas . The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals... Read More

12% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® Oncology revenues grew 13% year-over-year Submitted zanidatamab BLA for 2L BTC; expect to launch in 2025 or earlier Top-line Phase 2b data from suvecaltamide trial in essential tremor expected in late 1H24 2024 total revenue guidance affirmed at $4.0 to $4.2 billion DUBLIN , May 1, 2024 /PRNewswire/ -- Jazz... Read More

Overall survival and additional long-term follow-up data from the Phase 2b HERIZON-BTC-01 trial in previously treated HER2-positive metastatic biliary tract cancer (BTC) to be presented at ASCO 2024 DUBLIN , April 24, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology... Read More

DUBLIN , April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update. Audio... Read More

Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in treatment-resistant epilepsies Thirteen abstracts underscore Jazz's diverse neuroscience portfolio and pioneering efforts to continue advancing the treatment of serious sleep disorders, rare epilepsy syndromes and movement disorders DUBLIN , April 10, 2024 /PRNewswire/ -- Jazz... Read More

Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC) Confirmatory Phase 3 trial in first-line (1L) BTC open for enrollment at multiple global sites DUBLIN , April 2, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling... Read More

DUBLIN , March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19 , from 8:00 a.m. to 10:00 a.m. ET , focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic rationale and clinical data that support... Read More

Total revenues of $3.8 billion in 2023 and $1 billion in 4Q23 27% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® Oncology revenue surpassed $1 billion in 2023 Multiple late-stage pipeline catalysts anticipated in 2024 2024 total revenue guidance reflects continued top-line growth DUBLIN , Feb. 28, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today... Read More

Mr. Kennedy brings wealth of experience managing high growth organizations focused on creating value for shareholders DUBLIN , Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy , to its Board of Directors. Mr. Kennedy, Chair and Governor of the Bank of Ireland , has been appointed to the Jazz Board and will serve on the Audit... Read More

Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN , Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024 . Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in... Read More

DUBLIN , Feb. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: TD Cowen's 44th Annual Health Care Conference on Monday, March 4, 2024 Fireside chat at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 Fireside chat at 11:00 a.m. PT / 2:00 p.m.... Read More

DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2023 full year and fourth quarter financial results and provide a business and... Read More

Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales Preclinical program expands Jazz's pipeline of targeted oncology therapies DUBLIN and ALDERLEY PARK, United Kingdom , Feb. 7, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies... Read More

DUBLIN , Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant... Read More

DUBLIN , Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42 nd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 8, 2024 , at 2:15 p.m. PST / 10:15 p.m. GMT . A live audio webcast of the... Read More

First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant demonstrated a PFS of 67% at 6 months and a median PFS of 12 months in patients with heavily pre-treated HER2+/HR+ metastatic breast cancer (mBC) Efficacy and safety results support further investigation of this targeted combination therapy as a potential chemotherapy-free option for patients with... Read More

Data from nine abstracts to be presented, including real-world outcomes of Epidiolex ® (cannabidiol) in treatment-resistant focal epilepsies Presentations include data on U.S. caregiver-reported seizure and non-seizure outcomes in patients with tuberous sclerosis complex prescribed Epidiolex DUBLIN , Dec. 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored... Read More

New trial results of investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer Strong presence at ASH includes 11 presentations spanning Jazz's portfolio, advancing research into difficult-to-treat blood cancers and diseases Real-world data at NACLC reinforce clinical impact of Zepzelca ® (lurbinectedin) in small cell lung cancer DUBLIN , Nov. 30, 2023 /PRNewswire/ -- Jazz... Read More

Total Deal Value of Up to $770.5 million including Upfront Payment and Potential Milestone Payments Autifony Eligible to Receive Royalties on Future Net Sales STEVENAGE, England / Nov 14, 2023 / Business Wire / Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an... Read More

3Q23 total revenues of $972 million Combined revenues from key growth drivers, Xywav ® , Epidiolex ® and Rylaze ® , increased 24% year-over-year Raising total and Oncology revenue guidance at the mid-points Plan to initiate zanidatamab rolling biologics license application (BLA) submission this year for accelerated approval in second-line (2L) biliary tract cancers (BTC) DUBLIN , Nov. 8, 2023 /PRNewswire/ -- Jazz... Read More

DUBLIN and HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing... Read More

DUBLIN , Nov. 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference on Tuesday, November 14, 2023 Fireside chat at 4:30 a.m. PT / 7:30 a.m. ET / 12:30 p.m. GMT 6 th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 Fireside chat at 7:25 a.m. PT / 10:25... Read More

DUBLIN , Oct. 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2023 third quarter financial results and provide a business and financial update. Audio... Read More

Two presentations focus on cardiovascular disease risk among patients with sleep disorders and the impact of sodium intake on cardiometabolic comorbidities, highlighting the need for low-sodium treatment options TENOR study findings show that the most common patient-reported reasons for utilizing a Xywav individualized dosing regimen were to avoid morning grogginess, help fall asleep and improve sleep quality DUBLIN , Oct.... Read More

Meeting presentations underscore the increased need for awareness around the cardiovascular and cardiometabolic comorbidities and modifiable risk factors associated with sleep disorders Fourteen abstracts demonstrate Jazz Pharmaceuticals' continued leadership and commitment to expanding knowledge across rare sleep disorders DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that... Read More

Zanidatamab data demonstrate clinical potential of novel bispecific antibody in HER2-targeted biliary tract and gastric cancers Additional presentations, including a lurbinectedin oral presentation in small cell lung cancer (SCLC), underscore the strength of Jazz's solid tumor portfolio and the company's commitment to address difficult-to-treat tumors DUBLIN , Oct. 16, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:... Read More

DUBLIN , Sept. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted marketing authorization for Enrylaze ® (JZP458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients... Read More

DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences. TD Cowen 3 rd Annual Novel Mechanisms in Neuropsychiatry Summit Date: Wednesday, September 20, 2023 Location: Virtual Company management will participate in a fireside chat at 12:40 p.m. PT / 3:40 p.m. ET / 8:40 p.m. IST 2023 Cantor Fitzgerald Global... Read More

Renée Galá promoted to President and Chief Operating Officer DUBLIN , Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023 . Dan Swisher has notified the company of his intention to retire from his position as President and COO after five and a half years of... Read More

Six presentations demonstrated Jazz's commitment to providing solutions for people living with difficult-to-treat sleep disorders Review of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing DUBLIN , Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals... Read More

DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conference in Boston . Company management will participate in a fireside chat on Thursday, September 7, 2023 , at 8:20 a.m. PT / 11:20 a.m. ET / 4:20 p.m. IST . An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals... Read More

Strong execution delivered second quarter 2023 total revenues of $957 million Commercial excellence drove continued adoption of low-sodium Xywav ® ; net product sales increased 39% year-over-year Continued growth of Epidiolex ® ; net product sales increased 15% 2Q23 year-over-year Strong demand for Rylaze ® drove 39% increase in net product sales year-over-year Oncology portfolio expected to reach ~$1 billion in net product... Read More

MISSISSAUGA, ON , Aug. 2, 2023 /CNW/ - Jazz Pharmaceuticals Canada Inc. today announced that the Company has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Rylaze ® (crisantaspase recombinant) in Canada . 1 This allows for individual jurisdictions in Canada to begin formalizing access for eligible patients. Rylaze is indicated as a component of a multi-agent... Read More

DUBLIN , July 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on Wednesday, August 9, 2023 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 second quarter financial results and provide a business and financial update. Audio... Read More

DUBLIN , July 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization of JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute... Read More

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months (median study follow-up time of 12.4 months) Biliary tract cancers (BTC) are an aggressive group of cancers with... Read More

Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia DUBLIN , May 31, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2023, the 37 th annual meeting of the Associated Professional... Read More

DUBLIN , May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, June 13, 2023 , at 3:20 p.m. PT / 11:20 p.m. IST . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at... Read More

Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT DUBLIN , May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a webcast to review the zanidatamab biliary tract cancers (BTC) data being featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2 , 2023. Previously disclosed... Read More

Focus on commercial execution drove 1Q23 total revenues of $892.8 million Continued adoption of Xywav ® ; net product sales increased 49% 1Q23 compared to 1Q22 Confident in blockbuster potential of Epidiolex ® ; net product sales increased 20% 1Q23 compared to 1Q22 Strong Rylaze ® demand drove 58% increase in net product sales 1Q23 compared to 1Q22 Enhanced pipeline positioned to deliver at least three late-stage data... Read More

DUBLIN , May 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 RBC Capital Markets Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, May 16, 2023 , at 4:05 p.m. ET / 9:05 p.m. IST . An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at... Read More

Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor potential Nine abstracts accepted for presentation, including two oral presentations, reinforce Jazz's growing leadership in oncology and commitment to patients through clinically beneficial treatments and novel research Company to... Read More

DUBLIN , April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2023 first quarter financial results and provide a business and financial update. Interested parties... Read More

Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful data results in idiopathic hypersomnia and essential tremor DUBLIN , April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline,... Read More

Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations Research shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy DUBLIN , March 30, 2023... Read More

DUBLIN , March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023 . Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca ® (lurbinectedin), zanidatamab and JZP898. "The... Read More

MISSISSAUGA, ON , March 8, 2023 /CNW/ - Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced today that Vyxeos ® (daunorubicin and cytarabine liposome for injection) is now included on eight additional provincial drug formularies, including British Columbia , Ontario , Saskatchewan , Manitoba , New Brunswick , Nova Scotia , Alberta , and Newfoundland and Labrador . Vyxeos is indicated for the treatment of adults with newly... Read More

Strong Execution Drove Record Revenues in 2022 of $3.7 billion , an increase of 18% over 2021 Positioned for Total Revenue and Net Income Growth in 2023 Xywav Enters 2023 as the Oxybate Therapy of Choice and Company's Largest Product by Net Sales Enhanced Investment in R&D to Advance Pipeline towards Key Value Inflection Points in 2023 and 2024 Company is Well-Positioned to Achieve Vision 2025 DUBLIN , March 1, 2023... Read More

DUBLIN , Feb. 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference Date: Tuesday, March 7, 2023 Location: Boston Company management will participate in a fireside chat at 12:50 p.m. ET / 5:50 p.m. GMT A live audio webcast may be accessed via the Investors section of the Jazz... Read More

DUBLIN , Feb. 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 fourth quarter and full year financial results on Wednesday, March 1, 2023 , after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2022 fourth quarter and full year financial results and provide a business and... Read More

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 12.5 months Ongoing Phase 3 randomized clinical trial, HERIZON-GEA-01, has the potential to support regulatory submissions for zanidatamab in combination with chemotherapy as a therapeutic option... Read More

DUBLIN , Jan. 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41 st Annual J.P. Morgan Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 9, 2023 , at 3:45 p.m. PST / 11:45 p.m. GMT . A live audio webcast of the... Read More

Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC , Dec. 21, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab in key markets, including the U.S.,... Read More

Real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey presented at the 2022 American Epilepsy Society Annual Meeting expands evidence behind Epidiolex treatment in adult and pediatric patients Caregivers of Lennox-Gastaut Syndrome and Dravet Syndrome patients reported seizure and non-seizure related outcomes across age groups DUBLIN , Dec. 5, 2022 /PRNewswire/ -- Jazz Pharmaceuticals... Read More

Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S. caregiver-reported seizure and non-seizure outcomes in patients prescribed Epidiolex ® (cannabidiol) DUBLIN , Nov. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex ® (cannabidiol) oral solution presentations, including three late-breaking... Read More